<DOC>
	<DOCNO>NCT02655692</DOCNO>
	<brief_summary>The purpose study test safety efficacy repeat dos ketamine compare placebo , reduce symptom Posttraumatic Stress Disorder ( PTSD ) active duty military Veteran population .</brief_summary>
	<brief_title>CAP-Ketamine Antidepressant Resistant PTSD</brief_title>
	<detailed_description>In 2-site clinical trial , intend evaluate safety efficacy repeat dos ketamine treatment resistant PTSD , Veterans active duty military personnel meet criterion PTSD additional inclusion exclusion criterion randomize one three treatment arm ( placebo , low dose ketamine , high dose ketamine ) . Participants receive study drug via intravenous infusion twice per week 4-weeks .</detailed_description>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>male female Veterans active duty military personnel age 18 70 year diagnosis PTSD history trialing one antidepressant medication little PTSD symptom improvement ability provide write informed consent female currently pregnant breastfeed current risk suicide history severe head injury</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PTSD</keyword>
	<keyword>Ketamine</keyword>
	<keyword>Veteran</keyword>
	<keyword>Military</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>